Immunovant drops as market keeps pricing in batoclimab Phase 3 TED setback
Immunovant shares fell about 4.5% to $24.80 as investors continued digesting the April 2 Phase 3 thyroid eye disease (TED) topline miss for batoclimab. With batoclimab’s TED readout failing its primary endpoint, traders are refocusing on timelines and execution risk for next-generation IMVT-1402 programs.
1. What’s moving the stock
Immunovant (IMVT) traded lower after last week’s pivotal update in thyroid eye disease continued to pressure sentiment. On April 2, the company reported topline results from two Phase 3 studies of batoclimab in active, moderate-to-severe TED, and the program did not achieve statistical significance on the primary efficacy endpoint, despite a safety profile described as consistent with prior experience. (immunovant.com)
2. Why it matters to investors
The TED readout is a high-visibility checkpoint because it tests whether batoclimab can clear a late-stage efficacy bar in a competitive autoimmune indication. A primary-endpoint miss typically forces investors to reassess probability-of-success assumptions, potential partnering leverage, and how much of the company’s value must now be carried by IMVT-1402 rather than batoclimab.
3. What to watch next
Near-term trading is likely to track any additional detail the market can extract about the TED dataset (subgroups, secondary endpoints, durability) and management’s next steps for batoclimab. Separately, focus shifts to IMVT-1402 development progress and the cadence of upcoming topline updates in 2026–2027, as investors look for a clearer path to value creation beyond the challenged TED program.